

# Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease

Angelo D'Alessandro,<sup>1</sup> Kang Le,<sup>2</sup> Maureen Lundt,<sup>2</sup> Quan Li,<sup>3</sup> Emily B. Dunkelberger,<sup>3</sup> Troy Cellmer,<sup>3</sup> Andrew J. Worth,<sup>4</sup> Spurthi Patil,<sup>4</sup> Chris Huston,<sup>4</sup> Abby Grier,<sup>1</sup> Monika Dzieciatkowska,<sup>1</sup> Daniel Stephenson,<sup>1</sup> William A. Eaton<sup>3</sup> and Swee Lay Thein<sup>2</sup>

<sup>1</sup>Department of Biochemistry and Molecular Genetics, University of Colorado Denver – Anschutz Medical Campus, Aurora, CO; <sup>2</sup>Sickle Cell Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD; <sup>3</sup>Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD and <sup>4</sup>Agios Pharmaceuticals, Inc., Cambridge, MA, USA

**Correspondence:** A. D'Alessandro  
[angelo.dalessandro@cuanschutz.edu](mailto:angelo.dalessandro@cuanschutz.edu)

S.L. Thein  
[sweelay.thein@nih.gov](mailto:sweelay.thein@nih.gov)

**Received:** December 11, 2023.

**Accepted:** February 29, 2024.

**Early view:** March 7, 2024.

<https://doi.org/10.3324/haematol.2023.284831>

©2024 Ferrata Storti Foundation

Published under a CC BY-NC license



# SUPPLEMENTARY MATERIAL

## Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease

Angelo D'Alessandro,<sup>1,\*</sup> Kang Le,<sup>2</sup> Maureen Lundt,<sup>2</sup> Quan Li,<sup>3</sup> Emily B. Dunkelberger,<sup>3</sup> Troy Cellmer,<sup>3</sup> Andrew J. Worth,<sup>4</sup> Spurthi Patil<sup>4</sup>, Chris Huston<sup>4</sup>, Abby Grier,<sup>1</sup> Monika Dzieciatkowska,<sup>1</sup> Daniel Stephenson,<sup>1</sup> William A. Eaton,<sup>2</sup> Swee Lay Thein<sup>2,\*</sup>

- 1) Department of Biochemistry and Molecular Genetics, University of Colorado Denver – Anschutz Medical Campus, Aurora, CO, USA
- 2) Sickle Cell Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, United States;
- 3) Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, United States;
- 4) Agios Pharmaceuticals, Inc., Cambridge, MA, United States.

### \*Correspondence:

Angelo D'Alessandro, PhD  
Department of Biochemistry and Molecular Genetics  
University of Colorado Anschutz Medical Campus  
12801 East 17th Ave., Aurora, CO 80045  
Phone # 303-724-0096  
E-mail: [angelo.dalessandro@cuanschutz.edu](mailto:angelo.dalessandro@cuanschutz.edu)

Swee Lay Thein, MD  
National Institute of Health - NIH,  
National Heart, Lung and Blood Institutes, Bethesda, MD  
E-mail: [sweelay.thein@nih.gov](mailto:sweelay.thein@nih.gov)

### TABLE OF CONTENTS

|   |              |
|---|--------------|
| <b>SUPPLEMENTARY METHODS EXTENDED</b> ..... | <b>2</b>     |
| <b>SUPPLEMENTARY REFERENCES</b> .....       | <b>6</b>     |
| <b>SUPPLEMENTARY FIGURES</b> .....          | <b>7</b>     |
| <b>SUPPLEMENTARY FIGURE 1</b> .....         | <b>7</b>     |
| <b>SUPPLEMENTARY FIGURE 2</b> .....         | <b>8</b>     |
| <b>SUPPLEMENTARY FIGURE 3</b> .....         | <b>9</b>     |
| <b>SUPPLEMENTARY FIGURE 3</b> .....         | <b>10</b>    |
| <b>SUPPLEMENTARY DATA TABLE 1</b> .....     | <b>.XLSX</b> |

The Supplementary Table contains all raw data and elaborations.



















